ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

KALY Kali Inc (CE)

0.000001
0.00 (0.00%)
02 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Kali Inc (CE) USOTC:KALY OTCMarkets Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.000001 0.000001 0.000001 0.000001 31,100 01:00:00

KALY - Kali Extracts Announces Patented Cannabis Extracts Targeting $170 In Million Pharmaceutical Treatments

15/04/2019 2:10pm

InvestorsHub NewsWire


KALY – Kali Extracts Announces Patented Cannabis Extracts Targeting $170 In Million Pharmaceutical Treatments

 

Dallas, TX -- April 15, 2019 -- InvestorsHub NewsWire -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) has recently announced ongoing cannabis extract research and development targeting four specific health issues: Chronic Obstructive Pulmonary Disease (COPD); Type 2 Diabetes; Cancer Pain Management, and Epilepsy.  The market for Type 2 Diabetes is expected to be a $64 billion market by 2026.  The market for COPD treatment is anticipated to reach $14 billion by 2025The overall pain management treatment market is anticipated to reach $83 billion by 2024.  The market for epilepsy treatment is anticipated to reach $9 billion by 2022. The company has scheduled an online prestation this Wednesday, April 17th, where management will provide details on its patented cannabis extract treatments targeting a $170 million pharmaceutical market opportunity currently under development.  

Beyond the four specific cannabis therapies currently in various stages of research and development, KALY has a number of additional target therapies in its research pipeline which will be highlighted in the April 17tt presentation.

To learn more about the company visit https://www.kali-extracts.com/

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and as such, may involve risks and uncertainties. These forward looking statements relate to, amongst other things, current expectation of the business environment in which the company operates, potential future performance, projections of future performance and the perceived opportunities in the market. The company's actual performance, results and achievements may differ materially from the expressed or implied in such forward-looking statements as a result of a wide range of factors.

CONTACT:
Frederick Ferri
ir@kali-extracts.com

(214) 210-0459

 

1 Year Kali (CE) Chart

1 Year Kali (CE) Chart

1 Month Kali (CE) Chart

1 Month Kali (CE) Chart

Your Recent History

Delayed Upgrade Clock